Similar articles

• Cerebral atrophy in parkinsonism.

  Selby G. Selby G. Proc Aust Assoc Neurol. 1968;5(2):299-303. Proc Aust Assoc Neurol. 1968. PMID: 4884437 No abstract available.
• [Anatomo-clinical investigations on 100 parkinsonian patients examined by CAT (author's transl)].

  Quattrini A, Paggi A, Del Pesce M, Di Bella P, Menichelli F, Pasquini U, Salvolini U, Tascini G, Fuà P. Quattrini A, et al. Riv Patol Nerv Ment. 1978 Jul-Aug;99(4):207-34. Riv Patol Nerv Ment. 1978. PMID: 752182 Italian. No abstract available.
• [L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].

  Sano I, Taniguchi K. Sano I, et al. Munch Med Wochenschr. 1972 Oct 6;114(40):1717-9. Munch Med Wochenschr. 1972. PMID: 4538893 German. No abstract available.
• Surgical treatment of hydrocephalus ex-vacuo. Ventri- culoatrial shunt for degenerative brain disease.

  Salmon JH, Armitage JL. Salmon JH, et al. Neurology. 1968 Dec;18(12):1223-6. doi: 10.1212/wnl.18.12.1223. Neurology. 1968. PMID: 5304050 No abstract available.
• [Therapy of tparkinson's disease. Clinical and pharmacological viewpoints].

  Przuntek H. Przuntek H. Med Klin. 1979 Jul 13;74(28-29):1077-83. Med Klin. 1979. PMID: 39230 Review. German. No abstract available.